Skip Navigation Links

Bookmark and Share
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China
SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biolog...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.